Table 2.
Flow cytometry analysis of CD14, CD16, and CD163 markers on monocytes from BC patients depending on clinical response to NAC.
| Subset | BC without response, %, Median (Q1–Q3) | BC with response,%, Median (Q1–Q3) | Wilcoxon test, p-value |
|---|---|---|---|
| CD14+16- | 92.4 (88.07–98.00) | 93.14 (87.67–95.64) | 0.986 |
| CD14+16+ | 1.33 (0.52–3.10) | 2.24 (1.34–5.31) | 0.082 |
| CD14low16+ | 5.45 (2.01–10.23) | 2.24 (1.17–4.67) | 0.099 |
| CD14+16-163+ | 94.63 (90.74–97.49) | 96.66 (90.05–99.86) | 0.510 |
| CD14+16+163+ | 96.30 (89.79–99.18) | 98.78 (83.29–100) | 0.590 |
| CD14low16+163+ | 84.28 (33.11–99.02) | 98.58 (61.64–99.99) | 0.112 |